학술논문
A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.
Document Type
Journal
Author
Felip, Enriqueta; Brunsvig, Paal; Vinolas, Nuria; Ponce Aix, Santiago; Carcereny Costa, Enric; Domine Gomez, Manuel; Trigo Perez, Jose Manuel; Arriola, Edurne; Garcia Campelo, Rosario; Spicer, James F.; Thompson, Jonathan Robert; Ortega Granados, Ana Laura; Holt, Robert J.; Lorens, Katherine; Lorens, James B.; Shoaib, Muhammad; Siddiqui, Abdul; Schmidt, Emmett V.; Chisamore, Michael Jon; Krebs, Matthew
Source
Subject
Language
English
ISSN
15277755